Retroscreen Virology Group PLC Board Changes (4229J)
12 Juin 2014 - 8:01AM
UK Regulatory
TIDMRVG
RNS Number : 4229J
Retroscreen Virology Group PLC
12 June 2014
For immediate release 07.00: 12 June 2014
RETROSCREEN VIROLOGY GROUP PLC
("Retroscreen" or the "Company")
BOARD CHANGES
Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO
human challenge models of disease, is pleased to announce further
strategic changes to its Board of Directors ("Board") as part of
the Company's ambitious growth strategy. Jaime Ellertson has been
appointed as Non-Executive Chairman, with immediate effect,
succeeding David Norwood, who will continue to play a pivotal role
on the Board as a Non-Executive Director.
Jaime Ellertson (55) has a strong track record of leading fast
growing, data and service driven companies through phases of rapid
expansion, both in the private and public arena. Jaime is currently
Chairman and Chief Executive Officer of Everbridge Inc., a provider
of multidimensional critical communications solutions to leading
Health Care, Corporate and Government organisations globally. He
lives in Massachusetts and is a citizen of the United States of
America.
Jaime previously served as the Chief Executive Officer,
President and Director of Gomez Inc. a company specialising in
monitoring and managing Web site data and Web application
performance. During his tenure he led Gomez Inc. through an IPO
registration that resulted in the successful sale of the company
for $295M to Compuware Corporation (NASDAQ: CPWR). He served as
Chief Executive Officer, President and Director of S1 Corporation
Inc. (NASDAQ: SONE), a software provider to the financial services
marketplace. Jaime also orchestrated the highly successful
turnaround of Interleaf, Inc. (NASDAQ: LEAF), a provider of
software tools for e-content management, culminating in its
acquisition for $852M by BroadVision Inc in 2000. Earlier in his
career, Jaime founded several high growth software companies
including Openware Technologies Inc., Document Automation
Corporation and Purview Technologies Inc.. He has also served on
the boards of a number of public and private US and UK based
companies including those indicated below.
David Norwood was appointed Chairman of Retroscreen Virology
Limited in February 2011 and became Chairman of the Company in
April 2012. David remains as a Non-Executive Director of the
Company, with a focus on the Company's business growth and investor
strategy.
Kym Denny, Chief Executive Officer, commented, "Retroscreen is
expanding the application of its hVIVO platform to address key
bottlenecks in the pharmaceutical industry. I would like to welcome
Jaime Ellertson as our new Chairman, with his invaluable experience
of developing companies with novel ground breaking technologies
into world leaders. I would like to thank Dave for guiding
Retroscreen through its dramatic growth journey and I am delighted
that he will continue to serve on the Board. I am excited to work
with our newly shaped Board to deliver our broader vision on a
truly global scale."
Mr Ellertson is a director/ partner or has been a director/
partner of the following companies/ partnerships during the
previous five years:
Current
Calliope Corporation
Everbridge Europe Ltd.
Everbridge Inc.
Imodus Ltd.
MicroTech Ltd.
Peoplefluent Inc.
PJE Vero LLC.
Qvidian Corporation (previously Kadient Inc.)
Vocal Continuity Solutions Ltd.
Vocal Ltd.
Vocal Mobile Solutions Ltd.
Previous
Cloudfloor Corporation (acquired by Everbridge March 2011)
Danka Business Systems PLC
Gomez Europe Ltd.
Gomez Inc.
Yankee Group Research Inc.
Mr Ellertson does not hold any ordinary shares in the
Company.
Save for the information disclosed above there is no other
information to be disclosed on Mr Ellertson under Schedule 2(g) of
the AIM Rules.
For further information please contact:
Retroscreen Virology Group plc +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD)
Numis Securities Limited +44 207 260 1000
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)
Notes to Editors:
Retroscreen Virology Group plc ("Retroscreen") is a rapidly
growing UK life sciences company pioneering a technology platform
called hVIVO which uses human models of disease involving healthy
volunteers to study new drugs and investigate disease in a safe,
controlled environment.
Retroscreen has established itself as the world leader in this
field through the provision of clinical services to third party
study sponsors. To date, the Company has conducted over 35 clinical
studies, involving more than 1600 volunteers for a range of leading
industry, governmental and academic clients.
However, Retroscreen's hVIVO platform has a much wider
application in helping to understand illness better because the
Company believes that the best way to understand human disease is
by studying it in humans, not laboratory models.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOASFUFAFFLSESM
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Hvivo (LSE:HVO)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024